Literature DB >> 25496828

Diagnostic evaluation, monitoring, and perioperative management of spinal cord compression in patients with Morquio syndrome.

Joel Charrow1, Tord D Alden2, Catherine Ann R Breathnach3, Geoffrey P Frawley4, Christian J Hendriksz5, Bianca Link6, William G Mackenzie7, Renzo Manara8, Amaka C Offiah9, Martha L Solano10, Mary Theroux11.   

Abstract

Mucopolysaccharidosis IVA is an autosomal recessive condition caused by mutations in the GALNS gene, which encodes N-acetylgalactosamine-6-sulfatase, also called galactosamine-6-sulfatase (GALNS). A reduction in or absence of effective GALNS leads to faulty catabolism of keratan sulfate and chondroitin-6-sulfate within the lysosome; their accumulation causes cell, tissue, and organ dysfunction. The connective tissue, cartilage, ligaments, and bone of patients with Morquio A syndrome are particularly affected. Patients with Morquio A syndrome are at high risk of neurological complications because of their skeletal abnormalities; many patients are in danger of cervical myelopathy due to odontoid hypoplasia and ligamentous laxity leading to atlantoaxial subluxation. The multisystemic involvement of patients with Morquio A syndrome requires treatment by multidisciplinary teams; not all members of these teams may be aware of the potential for subluxation and quadriparesis. A multinational, multidisciplinary panel of 10 skeletal dysplasia or Morquio A syndrome specialists convened in Miami, FL on December 7 and 8, 2012 to develop consensus recommendations for early identification and effective management of spinal cord compression, for anesthesia and surgical best practices, and for effectual cardiac and respiratory management in patients with Morquio A syndrome. The target audience for these recommendations includes any physician who may encounter a patient with Morquio A syndrome, however doctors who do not have access to the full spectrum of specialists and resources needed to support patients with Morquio A syndrome should attempt to refer patients to a center that does. Physicians who manage Morquio A syndrome or comorbid conditions within specialty centers should review these expert panel recommendations and fully understand the implications of spinal cord instability for their own practices.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Atlanto axial fusion; GALNS protein, human; Intubation, endotracheal; MPS IVA; Practice guideline; Spinal cord compression

Mesh:

Year:  2014        PMID: 25496828     DOI: 10.1016/j.ymgme.2014.10.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  Spinal cord issues in adult patients with MPS: transition of care survey.

Authors:  Kemel A Ghotme; Fernando Alvarado-Gomez; Christina Lampe; Klane K White; Martha Solano-Villareal; Roberto Giugliani; Paul R Harmatz
Journal:  Childs Nerv Syst       Date:  2018-05-27       Impact factor: 1.475

2.  Outcomes from 18 years of cervical spine surgery in MPS IVA: a single centre's experience.

Authors:  A Broomfield; K Zuberi; J Mercer; G Moss; N Finnegan; P Hensman; R Walker; S Bukhari; N B Wright; F Stewart; S A Jones; R Ramirez
Journal:  Childs Nerv Syst       Date:  2018-06-26       Impact factor: 1.475

Review 3.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

4.  Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

Authors:  Mehmet Umut Akyol; Tord D Alden; Hernan Amartino; Jane Ashworth; Kumar Belani; Kenneth I Berger; Andrea Borgo; Elizabeth Braunlin; Yoshikatsu Eto; Jeffrey I Gold; Andrea Jester; Simon A Jones; Cengiz Karsli; William Mackenzie; Diane Ruschel Marinho; Andrew McFadyen; Jim McGill; John J Mitchell; Joseph Muenzer; Torayuki Okuyama; Paul J Orchard; Bob Stevens; Sophie Thomas; Robert Walker; Robert Wynn; Roberto Giugliani; Paul Harmatz; Christian Hendriksz; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

5.  Adjunct Diagnostic Value of Transcranial Magnetic Stimulation in Mucopolysaccharidosis-Related Cervical Myelopathy: A Pilot Study.

Authors:  Mariagiovanna Cantone; Giuseppe Lanza; Alice Le Pira; Rita Barone; Giovanni Pennisi; Rita Bella; Manuela Pennisi; Agata Fiumara
Journal:  Brain Sci       Date:  2019-08-14

6.  A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months.

Authors:  Akari Nakamura-Utsunomiya; Toshio Nakamae; Reiko Kagawa; Shuhei Karakawa; Sonoko Sakata; Fumiaki Sakura; Chihiro Tani; Yoshiko Matsubara; Takashi Ishino; Go Tajima; Satoshi Okada
Journal:  Int J Mol Sci       Date:  2020-02-02       Impact factor: 5.923

7.  Amplitude-reduction alert criteria and intervention during complex paediatric cervical spine surgery.

Authors:  William M McDevitt; Laura Quinn; W S B Wimalachandra; Edmund Carver; Catalina Stendall; Guirish A Solanki; Andrew Lawley
Journal:  Clin Neurophysiol Pract       Date:  2022-07-28

8.  Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses?

Authors:  N Williams; D Challoumas; D M Eastwood
Journal:  J Child Orthop       Date:  2017-08-01       Impact factor: 1.548

9.  Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS).

Authors:  Karolina M Stepien; Anait K Gevorkyan; Christian J Hendriksz; Tinatin V Lobzhanidze; Jordi Pérez-López; Govind Tol; Mireia Del Toro Riera; Nato D Vashakmadze; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2020-05-14       Impact factor: 4.123

Review 10.  Cerebral and occipito-atlanto-axial involvement in mucopolysaccharidosis patients: clinical, radiological, and neurosurgical features.

Authors:  Carlo Giussani; Lelio Guida; Francesco Canonico; Erik P Sganzerla
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.